PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer- United Kingdom

doi 10.1038/sj.bjc.6605471

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated With Cetuximab

Drugs in R and D
Pharmacology
2011English

Current Status of Treatment of Metastatic Colorectal Cancer With Special Reference to Cetuximab and Elderly Patients

OncoTargets and Therapy
OncologyPharmacology
2008English

Mechanism of Resistance to Cetuximab Therapy in Colorectal Cancer

mAbs
AllergyImmunology
2012English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Inhibition of SLC1A5 Sensitizes Colorectal Cancer to Cetuximab

International Journal of Cancer
Cancer ResearchOncology
2018English

Inhibition of SLC1A5 Sensitizes Colorectal Cancer to Cetuximab

International Journal of Cancer
Cancer ResearchOncology
2019English

Metastatic Colorectal Cancer Treated With FOLFOX + Cetuximab in Long Term Use Protocol - Complete Responses and Acceptable Tolerability Profile - Case Series

International Archives of Medicine
2015English

Pretreatment Immune Status Correlates With Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients

Cancer immunology research
Cancer ResearchImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy